AU5717400A - Cancer therapy - Google Patents
Cancer therapyInfo
- Publication number
- AU5717400A AU5717400A AU57174/00A AU5717400A AU5717400A AU 5717400 A AU5717400 A AU 5717400A AU 57174/00 A AU57174/00 A AU 57174/00A AU 5717400 A AU5717400 A AU 5717400A AU 5717400 A AU5717400 A AU 5717400A
- Authority
- AU
- Australia
- Prior art keywords
- agent
- cell
- immunotherapeautic
- cam
- advanced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ336259 | 1999-06-14 | ||
| NZ33625999 | 1999-06-14 | ||
| PCT/NZ2000/000098 WO2000076497A1 (en) | 1999-06-14 | 2000-06-14 | Cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU5717400A true AU5717400A (en) | 2001-01-02 |
Family
ID=19927331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU57174/00A Abandoned AU5717400A (en) | 1999-06-14 | 2000-06-14 | Cancer therapy |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040086498A9 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1189611B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP4638098B2 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE324888T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU5717400A (cg-RX-API-DMAC10.html) |
| DE (1) | DE60027719T2 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2265948T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2000076497A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001247459A (ja) | 2000-03-03 | 2001-09-11 | Oakland Uniservices Ltd | 癌の組み合わせ療法 |
| ES2243466T3 (es) * | 2000-03-31 | 2005-12-01 | Angiogene Pharmaceuticals Ltd | Terapias en dosis divididas con actividad dañina vascular. |
| US20070021392A1 (en) * | 2000-03-31 | 2007-01-25 | Davis Peter D | Divided dose therapies with vascular damaging activity |
| EP1311262A4 (en) * | 2000-07-28 | 2005-06-01 | Cancer Rec Tech Ltd | CANCER THERAPY THROUGH COMBINATION THERAPY |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| FR2832154B1 (fr) | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
| GB2384428A (en) * | 2002-01-29 | 2003-07-30 | Thromb X Nv | Inhibitors of HIF |
| GB2386836B (en) * | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| ES2649817T3 (es) | 2002-04-05 | 2018-01-15 | Roche Innovation Center Copenhagen A/S | Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á |
| NZ520321A (en) * | 2002-07-19 | 2005-03-24 | Auckland Uniservices Ltd | Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal |
| US20040067255A1 (en) * | 2002-10-07 | 2004-04-08 | Chaplin David J. | Method of administering split doses of a vascular targeting agent |
| GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
| US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
| US8198427B1 (en) | 2002-11-14 | 2012-06-12 | Dharmacon, Inc. | SiRNA targeting catenin, beta-1 (CTNNB1) |
| US7619081B2 (en) | 2002-11-14 | 2009-11-17 | Dharmacon, Inc. | siRNA targeting coatomer protein complex, subunit beta 2 (COPB2) |
| US7951935B2 (en) | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
| US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
| US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
| US7635770B2 (en) | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
| US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US7977471B2 (en) | 2002-11-14 | 2011-07-12 | Dharmacon, Inc. | siRNA targeting TNFα |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US7691998B2 (en) | 2002-11-14 | 2010-04-06 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
| US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
| JP4546454B2 (ja) * | 2003-01-28 | 2010-09-15 | レクサーン・コーポレイション | Hif−1発現を抑制するアンチセンスオリゴヌクレオチド |
| CA2513398C (en) * | 2003-01-31 | 2013-09-10 | Rexahn Corporation | Antisense oligonucleotides that inhibit expression of hif-1 |
| FR2835838B1 (fr) * | 2003-02-06 | 2007-11-16 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene codant pour un facteur de transcription |
| US20050070474A1 (en) * | 2003-04-28 | 2005-03-31 | Krissansen Geoffrey Wayne | Methods of treatment and compositions therefor |
| GB0321999D0 (en) * | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
| US20070218551A1 (en) * | 2003-10-02 | 2007-09-20 | Chuan-Yuan Li | Novel Sirna-Based Approach to Target the Hif-Alpha Factor for Gene Therapy |
| US7605250B2 (en) | 2004-05-12 | 2009-10-20 | Dharmacon, Inc. | siRNA targeting cAMP-specific phosphodiesterase 4D |
| US7618947B2 (en) * | 2004-08-25 | 2009-11-17 | Isis Pharmaceuticals, Inc. | Modulation of HIF-1 beta expression |
| US9447138B2 (en) | 2004-11-09 | 2016-09-20 | Roche Innovation Center Copenhagen A/S | Potent LNA oligonucleotides for the inhibition of HIF-1a expression |
| BRPI0515726A8 (pt) | 2004-11-09 | 2017-09-12 | Santaris Pharma As | Oligonucleotídeos de lna potentes para a inibição de expressão de hif-1a |
| BRPI0614965A2 (pt) * | 2005-08-26 | 2016-09-13 | Antisoma Plc | método para a modulação de crescimento neoplástico, usos de um composto ou, um sal, éster ou pró-droga farmaceuticamente aceitável do mesmo, de um aglutinante do fator de crescimento endotelial vascular, e de um taxano, formulação farmacêutica, e, kit |
| CA2874490C (en) | 2012-05-23 | 2021-11-16 | The Ohio State University | Tertiary quaternary amine-based cationic lipid nanoparticle compositions and methods of making and methods of using the same |
| EP2858722B8 (en) | 2012-06-08 | 2018-02-21 | Aduro BioTech, Inc. | Compostions and methods for cancer immunotherapy |
| JP2016524593A (ja) | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| US10176292B2 (en) | 2013-07-31 | 2019-01-08 | Memorial Sloan-Kettering Cancer Center | STING crystals and modulators |
| JP2016538344A (ja) * | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | 癌処置としてのstingアゴニストの使用 |
| JP6762030B2 (ja) * | 2014-11-20 | 2020-09-30 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 異なる核酸アジュバントの組み合わせによる、新規Th1誘導性アジュバントおよびその用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3655470A (en) * | 1969-03-29 | 1972-04-11 | Toa Gosei Chem Ind | Process for the production of a foamed thermoplastic resin sheet |
| FR2516922A1 (fr) * | 1981-11-25 | 1983-05-27 | Lipha | Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant |
| DE3587500T2 (de) * | 1984-12-04 | 1993-12-16 | Lilly Co Eli | Tumorbehandlung bei Säugetieren. |
| US4704355A (en) * | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| US5281620A (en) * | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
| DE3789299T2 (de) * | 1986-12-23 | 1994-08-04 | Warner Lambert Co | Verbindungen mit antitumoralen und antibakteriellen Eigenschaften. |
| JPH01193227A (ja) * | 1988-01-29 | 1989-08-03 | Res Dev Corp Of Japan | 癌免疫療法補助剤 |
| US5075287A (en) * | 1989-03-03 | 1991-12-24 | Nisshin Oil Mills, Inc. | Muramyl peptide derivatives and immunoregulating compositions containing them |
| JPH03116857A (ja) * | 1989-09-29 | 1991-05-17 | Mitsui Petrochem Ind Ltd | 発光または受光装置 |
| US5250296A (en) * | 1990-11-29 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine |
| US5620875A (en) * | 1995-02-17 | 1997-04-15 | University Of Portland | Transfer of taxol from yew tree cuttings into a culture medium over time |
| JPH0940690A (ja) * | 1995-05-23 | 1997-02-10 | Yutaka Sashita | ステロイド配糖体及びこれを有効成分とする医薬 |
| US5882914A (en) * | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
| US5977077A (en) * | 1995-08-28 | 1999-11-02 | Interlab Corporation | Xanthone analogs for the treatment of infectious diseases |
| US5863904A (en) * | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
| CA2274908A1 (en) * | 1996-12-13 | 1998-06-18 | Eli Lilly And Company | Leukotriene antagonists for cerebral focal stroke |
| US5910505A (en) * | 1997-03-21 | 1999-06-08 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma |
| US5998454A (en) * | 1997-03-21 | 1999-12-07 | Eli Lilly And Company | Leukotriene antagonists useful for treating iritis |
| US5914340A (en) * | 1997-03-21 | 1999-06-22 | Eli Lilly And Company | Leukotriene antagonists useful for treating dermatoses |
| DE19721211A1 (de) * | 1997-05-21 | 1998-11-26 | Lindner Sen Wolfgang Dr Med | Kombination von antientzündlichen Wirkstoffen mit immunstimulierenden Agentien und zytotoxischen Agentien zur Behandlung von Tumoren |
| US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
| DE60018225T2 (de) * | 1999-03-01 | 2005-12-29 | Pfizer Products Inc., Groton | Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor |
| US6806257B1 (en) * | 1999-10-20 | 2004-10-19 | Board Of Trustees Of Southern Illinois University | Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators |
| CA2400197A1 (en) * | 2000-02-17 | 2001-08-23 | Merck & Co., Inc. | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
| JP2001247459A (ja) * | 2000-03-03 | 2001-09-11 | Oakland Uniservices Ltd | 癌の組み合わせ療法 |
| EP1311262A4 (en) * | 2000-07-28 | 2005-06-01 | Cancer Rec Tech Ltd | CANCER THERAPY THROUGH COMBINATION THERAPY |
| GB0121285D0 (en) * | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2386836B (en) * | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| GB0321999D0 (en) * | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
-
2000
- 2000-06-14 JP JP2001502830A patent/JP4638098B2/ja not_active Expired - Fee Related
- 2000-06-14 DE DE60027719T patent/DE60027719T2/de not_active Expired - Lifetime
- 2000-06-14 EP EP00942571A patent/EP1189611B1/en not_active Expired - Lifetime
- 2000-06-14 WO PCT/NZ2000/000098 patent/WO2000076497A1/en not_active Ceased
- 2000-06-14 AU AU57174/00A patent/AU5717400A/en not_active Abandoned
- 2000-06-14 AT AT00942571T patent/ATE324888T1/de not_active IP Right Cessation
- 2000-06-14 ES ES00942571T patent/ES2265948T3/es not_active Expired - Lifetime
-
2001
- 2001-12-11 US US10/014,887 patent/US20040086498A9/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20030003092A1 (en) | 2003-01-02 |
| ATE324888T1 (de) | 2006-06-15 |
| EP1189611A4 (en) | 2003-05-02 |
| ES2265948T3 (es) | 2007-03-01 |
| DE60027719T2 (de) | 2007-04-26 |
| WO2000076497A1 (en) | 2000-12-21 |
| JP2003501460A (ja) | 2003-01-14 |
| DE60027719D1 (de) | 2006-06-08 |
| JP4638098B2 (ja) | 2011-02-23 |
| EP1189611A1 (en) | 2002-03-27 |
| US20040086498A9 (en) | 2004-05-06 |
| EP1189611B1 (en) | 2006-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60027719D1 (de) | Krebstherapie | |
| Serša et al. | Electrochemotherapy: variable anti-tumor effect on different tumor models | |
| KR960703616A (ko) | 킬러 세포 개재 세포용해를 위한 암세포의 감작 방법 | |
| EP0972517A3 (en) | Use of 1,2,4-benzotriazine oxides for the preparation of a medicament for the treatment of tumours | |
| GEP20053688B (en) | Substituted-Triazolopyrimidines as Anticancer Agents | |
| US5955059A (en) | Use of locally applied DNA fragments | |
| CA2276180A1 (en) | Method for activating human antigen-presenting cells, activated human antigen-presenting cells, and use thereof | |
| CA2291065A1 (en) | Raf kinase inhibitors | |
| WO2001039762A3 (en) | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system | |
| JPH01254623A (ja) | スフインゴ糖脂質代謝の阻害剤を有効成分として含有する癌治療薬 | |
| AU5549586A (en) | Therapeutic use of tin mesoporphyrin | |
| DK0964690T3 (da) | Peptid-lipidkonjugater, liposomer og liposomal lægemiddeladministration | |
| KONDO et al. | Nitric oxide production in mouse peritoneal macrophages enhanced with glycyrrhizin | |
| HK1046846A1 (zh) | 包含boroproline的抗肿瘤复合物 | |
| Passi et al. | The oxyradical-scavenging activity of azelaic acid in biological systems | |
| AU5873998A (en) | Quinazolinone compounds | |
| CA2388939A1 (en) | Therapeutic treatments for blood cell deficiencies | |
| ATE247949T1 (de) | Arzneistoffverabreichungssystem mit zweistufigem targeting | |
| WO1990006748A3 (en) | Use of certain herbicides in cancer treatment and production of protoporphyrin ix | |
| WO1999007383B1 (en) | Composition and method for regulating cell proliferation and cell death | |
| NO20050793L (no) | Anvendelse av urease for inhibering av kreftcellevekst | |
| AU8355598A (en) | The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in phot odynamictherapy and certain such novel derivatives | |
| NO20021011L (no) | Fremgangsmåte og formulering for tumortilbakegang og suppresjon av cancerceller | |
| AU6349400A (en) | Methods for treatment of hyperproliferative diseases using human mda-7 | |
| Packer et al. | Boron neutron capture therapy of anterior chamber melanoma with p-boronophenylalanine. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |